Nifedipine
Nifedipine is a calcium channel blocker, of the dihydropyridine type. The US label read is for nifedipine extended-release tablets and lists two uses: the management of vasospastic angina, and the management of chronic stable angina without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers or organic nitrates, or who cannot tolerate those agents. No brand-name nifedipine label was found in openFDA, so this page rests on a generic manufacturer's label.
Also called Nifedipine extended-release tablets
- Drug
- In this atlas
Overview
Technical summary
RxNorm ingredient 7417; UNII I9ZF7L6G2L. MeSH descriptor D009543 is Nifedipine. Class: Dihydropyridine Calcium Channel Blocker (FDA established pharmacologic class, RxClass). The label read is the nifedipine extended-release tablets, Upsher-Smith Laboratories, LLC label, effective 2026-01-19 in openFDA (application ANDA203126). Other nifedipine labels in openFDA, from other sponsors and repackagers, were not read. This page records label indications and the class only: no trial result and no dose is given.
Trials at a glance
The figures count the 9 registry trials in this atlas that name this drug or a product that contains it. Trials that use another name for it are not counted.
- Trials
- 9
- Phase 3 or 4
- 9
- Recruiting
- 1
- Regulatory decisions
- 0
| Phase | Recruiting | Completed | Unknown status | All statuses |
|---|---|---|---|---|
| Phase 3 | 0 | 2 | 0 | 2 |
| Phase 4 | 1 | 5 | 1 | 7 |
| All phases | 1 | 7 | 1 | 9 |
Conditions these trials study
Sponsors with the most trials
- Bayer
- Gynuity Health Projects
- Icahn School of Medicine at Mount Sinai
- Istituto Auxologico Italiano
- Maastricht University Medical Center
About this drug
- Level
- Substance
- Mechanism
- Not reported
Claims and evidence
Context People for whom the US label of nifedipine extended-release tablets lists an indication: vasospastic angina, chronic stable angina
- Recipient
- Recipient not specified
- Population
- Patients described in the indications section of the label. The label does not state an age range in the passages read.
- Care setting
- Prescription medicine, as described in the US label
- Geography
- United States (label of the US Food and Drug Administration)
- Life stage
- Not stated in the label passages read
- Gestational age
- Not reported
- Postnatal age
- Not reported
- Follow-up
- Not applicable (label statement)
Eligibility: 2 inclusion criteria; exclusion criteria not stated
- Included
- Patients with vasospastic angina
- Patients with chronic stable angina without evidence of vasospasm who remain symptomatic despite adequate doses of beta blockers or organic nitrates, or who cannot tolerate those agents
- Excluded
- None stated
The US label of nifedipine extended-release tablets, in the Upsher-Smith Laboratories, LLC version dated 2026-01-19 in openFDA, lists the medicine for the management of vasospastic angina, and for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers or organic nitrates, or who cannot tolerate those agents.
Applies to Recipient not specified People for whom the US label of nifedipine extended-release tablets lists an indication: vasospastic angina, chronic stable angina
- Certainty method
- Not assessed
- Limitations
- This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
- Last checked
- 2026-11-09
- Next evidence check due
- Not scheduled
Sources and citations (2)
-
- Locator
- results[0].indications_and_usage[0]
- How it applies
- The label sentences that give the indications named in the statement, each quoted in the research quote table.
- Retrieved
- Source effective date
- 2026-01-19
- Source state
- Current
- Version fingerprint
c069ea3c1e7516d4e5f12ff730186c2bc09b702825b261ac8c2355a7f2758fdf- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
-
- Locator
- results[0].effective_time
- How it applies
- Effective date of the label text read, 20260119.
- Retrieved
- Source effective date
- 2026-01-19
- Source state
- Current
- Version fingerprint
c069ea3c1e7516d4e5f12ff730186c2bc09b702825b261ac8c2355a7f2758fdf- Reuse basis
- openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-09, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
FDA label
The FDA label of the application holder, as the openFDA label dataset holds it, for the products that contain this drug.
ADALAT
No label from the application holder was found in the openFDA label dataset for application NDA019478. This page does not show another labeler's label in its place.
ADALAT CC
No label from the application holder was found in the openFDA label dataset for application NDA020198. This page does not show another labeler's label in its place.
PROCARDIA
No label from the application holder was found in the openFDA label dataset for application NDA018482. This page does not show another labeler's label in its place.
PROCARDIA XL
No label from the application holder was found in the openFDA label dataset for application NDA019684. This page does not show another labeler's label in its place.
FDA decisions timeline
The regulatory decisions of the FDA that this atlas holds for this drug and the products that contain it, oldest first. Each links to its full record.
Clinical links
Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.
-
Claim, not a settled fact FDA label lists the management of chronic stable angina without evidence of vasospasm, in patients who remain symptomatic on beta blockers or organic nitrates or cannot tolerate them, as an indication: Stable angina
Applies to Recipient not specified People for whom the US label of nifedipine extended-release tablets lists an indication: vasospastic angina, chronic stable angina
The US label of nifedipine extended-release tablets, in the Upsher-Smith Laboratories, LLC version dated 2026-01-19 in openFDA, lists the medicine for the management of vasospastic angina, and for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers or organic nitrates, or who cannot tolerate those agents.Limitations. This claim records what the label says the medicine is indicated for. It is not a finding about how well the medicine works, and no trial result is recorded for it in this atlas. The label may list other indications that were not recorded. Contraindications, doses, interactions and warnings were not read. Labels change, and openFDA also lists other versions with different dates. openFDA's own disclaimer says not to rely on it for decisions about medical care.
Registry records
Assembled by a program from ClinicalTrials.gov and openFDA. No person wrote or checked these pages, and they are counted apart from the pages that people wrote. Lists of trials come from the registry's own coding and may miss trials.
Registry products 4
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and 2 efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
-
A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.
Registry trials 9
Record details
- Record id
cardio:nifedipine- Content hash
bb9b665dc477357852bb7e7137490499e0a32d6b236c06984cd2b31afcac7667